SCHEMBL3010666

SCHEMBL3010666

COc1ccc(Br)cc1S(=O)(=O)N1CCN(c2nc(Cc3cccc(C)c3C)cs2)CC1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.48
MAPT P10636 2/20 0.48
RECQL P46063 2/20 0.48
GAA P10253 3/20 0.48
USP2 O75604 3/20 0.43
HTT P42858 2/20 0.43
L3MBTL1 Q9Y468 2/20 0.43
LMNA P02545 1/20 0.43
TP53 P04637 1/20 0.42
ALOX15 P16050 1/20 0.42
POLB P06746 1/20 0.41
TSHR P16473 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
KMT2A Q03164 3/20 0.41
HSD17B10 Q99714 2/20 0.40
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40
MAPK1 P28482 1/20 0.39
KDM4E B2RXH2 1/20 0.39
DRD2 P14416 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3645891 0.97 ALDH1A1 (0.46) ALDH1A1MAPTRECQLGAAUSP2
SCHEMBL3003923 0.93 GAA (0.49) ALDH1A1MAPTRECQLGAAUSP2
SCHEMBL3019130 0.91 ALDH1A1 (0.49) ALDH1A1MAPTRECQLGAAUSP2
SCHEMBL3010426 0.91 ALDH1A1 (0.61) ALDH1A1MAPTRECQLGAAUSP2
SCHEMBL3002376 0.91 ALDH1A1 (0.51) ALDH1A1MAPTRECQLGAAUSP2
SCHEMBL3015128 0.90 GAA (0.51) ALDH1A1MAPTRECQLGAAUSP2
SCHEMBL3019492 0.87 GAA (0.48) ALDH1A1MAPTRECQLGAAUSP2
SCHEMBL3012131 0.87 TP53 (0.40) ALDH1A1MAPTRECQLUSP2LMNA
SCHEMBL3017903 0.87 PKM (0.37) ALDH1A1MAPTRECQLGAAHTT
SCHEMBL3015574 0.86 GAA (0.51) ALDH1A1MAPTRECQLGAAUSP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA ALDH1A1 3510/4885MAPT 18/4885RECQL 1564/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.